FIELD OF INVENTION

The present invention relates to a process for preparation of a novel crystalline form of Glucuronic acid addition salt of Sunitinib (I) termed as Form-SG2. Form-SG2 of Sunitinib Glucuronate (I) is crystalline in nature and is characterized by X-ray powder diffraction pattern comprising of at least three 29° peaks selected from the XRPD peak set of 3.9, 14.6, 18.4, 25.6 and 27.6 ± 0.2 20°, wherein diffraction angle peak at about 18.4 ± 0.2 20° is a single un-split peak. The crystalline Form-SG2 of Sunitinib Glucuronate may be useful as an anti-cancer agent.

BACKGROUND OF THE INVENTION

Sunitinib is chemically described as N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro- 1,2-dihydro-2-oxo-3/f-indol-3-ylidine)methyl]-2,4-dimethyl-li/-pyrrole-3-carboxamide and is represented by Formula (la). Formula (la) The malic acid salt of Sunitinib is a kinase inhibitor and has been approved by USFDA as SUTENT™ for the treatment of Gastrointestinal Stromal Tumor (GIST) after disease progression on or intolerance to imatinib mesylate, advanced Renal Cell Carcinoma (RCC) and progressive, well-differentiated pancreatic NeuroEndocrine Tumors (pNET) in patients with unresectable locally advanced or metastatic disease.

Tang et al in US 6573293 B2 and WO 01/060814 A2 provided the first disclosure of Sunitinib base and Sunitinib malate salt. This patent application discloses general salts of Sunitinib such as acid addition salts and salts formed when acidic proton present in the parent compound is either replaced by a metal ion or coordinates with an organic base. However, this patent does not describe about the preparation of any salts of Sunitinib and their polymorphic forms.
Besides the malic acid salt of Sunitinib, there are very few disclosures of other salt forms of Sunitinib, viz. - Mangion et al in WO 2010/041134 Al in the entire patent specification describe the process for preparation of only acetic acid salt of Sunitinib. Further, Selic et al in WO 2010/049449 A2 describe the process for preparation of tartaric acid and citric acid salts of Sunitinib. Also, recently Dehury et al in WO2013140232 Al described the few pharmaceutically acceptable acid addition salts of Sunitinib wherein the pharmaceutically acceptable acid addition salts mentioned are malonic acid, oxalic acid, ferulic acid, succinic acid, p-coumaric acid, sinapic acid, caffeic acid, maliec acid, fumaric acid and phosphoric acid.

Besides the aforementioned disclosures, still there appears to be a need for new solid forms of Sunitinib having further improved physical and/or chemical properties. Hence it was thought worthwhile by the inventors of the present application to explore novel pharmaceutically acceptable salts of Sunitinib, which may further improve the characteristics of drug Sunitinib. Inventors of the present application thus reported glucuronic acid addition salt of Sunitinib in the co-pending IN patent application 1629/CHE/2013. The choice of glucuronic acid for salt formation with Sunitinib base has been based on the premise that this salt is pharmaceutically acceptable and has favorable safety profile.

Crystalline form of Glucuronic acid addition salt of Sunitinib, obtained by following the process of Example-2 of IN patent application 1629/CHE/2013, is characterized by XRPD peak set of 10.1, 11.3, 13.7, 15.1, 18.6, 19.7 and 24.9 ± 0.2 20° and DSC isotherm comprising of at least one endothermic peak ranging between 160 to 185 °C or between 210 to 230 °C, but without any DSC peak below 140 °C. This polymorphic form of Glucuronic acid addition salt of Sunitinib mentioned in 1629/CHE/2013 may be referred to as Form-SGl.

Existence of polymorphism is known to be a unique phenomenon in solid materials, wherein existence of different physical forms including shape, size, and arrangement of molecules in the physical state or polymorphs of same compound are known in the nature. A single compound, or a salt complex, may give rise to a variety of solids having distinct physical properties, which often results in substantial differences in bioavailability, stability, and other differences between production lots of formulated pharmaceutical products. Due to this reason, since polymorphic forms can vary in their chemical and physical properties, regulatory authorities often require that efforts be made to identify all polymorphic forms, e.g., hydrate or anhydrate, crystalline or amorphous, solvated or un-solvated forms, etc. of the drug substances. However, the existence, and possible numbers, of polymorphic forms for a given compound cannot be predicted. In addition, there are no "standard" procedures that can be used to prepare polymorphic forms of a substance.

Alternate new polymorphic forms of pharmaceutically active / useful compound provide an opportunity to improve the drug performance characteristics of such product. Further, discovery of additional polymorphic forms may help in the identification of the polymorphic content of a batch of an active pharmaceutical ingredient. Therefore, inventors of the present application provide a new stable crystalline form of Sunitinib Glucuronate designated as Form-SG2. Crystalline Sunitinib Glucuronate Form-SG2 is very stable and has been found to retain its characteristic features in stability studies even up to 6 months, wherein the physicochemical properties remain substantially the same. This stable form offers various advantages in terms of storage, shelf life, solubility, safety profile and improved physical and/or chemical properties.
Present invention also provides the process for preparation of crystalline Sunitinib Glucuronate Form-SG2, which is easily achievable, commercially viable and amenable for up scaling.

SUMMARY OF THE INVENTION:

Particular aspects of the present specification relate to a new stable crystalline form of Sunitinib Glucuronate (I) designated as Form-SG2 and processes for its preparation.
In one aspect of the present application, the present invention provides a process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), comprising the steps of:

a) providing a solution of Sunitinib base in ethanol at temperature ranging from 20-35 °C;
b) raising the temperature of reaction mixture to a temperature of 50-55 °C;
c) addition of aq. solution of D(-)glucuronic acid of Formula (A) to the reaction mixture, wherein the addition is performed slowly over time duration of 10-30 mins;
d) stirring the reaction mixture for time duration ranging from 30 mins to 1 hr;
e) cooling the reaction mixture to a temperature of 20-30 °C, wherein rate of cooling shall not exceed 1 °C/ minute;
f) subjecting the reaction mixture obtained from step e) to continuous stirring for the time duration of 4-6 hrs;
g) isolating the crystalline Form-SG2 of Sunitinib Glucuronate (I). In a further aspect of the present application, crystalline Form-SG2 of Sunitinib Glucuronate contains Sunitinib base and glucuronic acid in about 1:1 proportion. In another aspect of the present application, Form-SG2 of Sunitinib Glucuronate (I) obtained by the process of the present invention is crystalline in nature and is characterized by X-ray powder diffraction pattern comprising of at least three 20° peaks selected from the XRPD peak set of 3.9, 14.6, 18.4, 25.6 and 27.6 ± 0.2 20°, wherein diffraction angle peak at about 18.4 ± 0.2 29° is a single un-split peak and DSC isotherm comprising of at least one endothermic peak ranging between 115 to 130 °C.
In another aspect, the present invention also relates to a composition comprising crystalline Form-SG2 of Sunitinib Glucuronate together with one or more pharmaceutically acceptable excipients, which may be useful in the treatment of various cancerous disorders. Further particular aspects of the present invention are detailed in the description of the invention, wherever appropriate.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is an example of X-ray powder diffraction ("XRPD") pattern of crystalline Form-SG2 of Sunitinib Glucuronate
Fig. 2 is an example of Differential Scanning Calorimetry ("DSC") curve of crystalline Form-SG2 of Sunitinib Glucuronate
Fig.3 is an example of Thermo-Gravimetric Analysis ("TGA") thermogram of crystalline Form-SG2 of Sunitinib Glucuronate

ABBREVIATIONS

DETAILED DESCRIPTION

As set forth herein, embodiments of the present invention relate to a new stable crystalline form of Sunitinib Glucuronate (I) designated as Form-SG2 and processes for its preparation.
In one embodiment of the present application, crystalline Form-SG2 of Sunitinib Glucuronate contains Sunitinib base and glucuronic acid in a ratio of about 1:1. Ratio of about 1:1 means that the glucuronic acid addition salt of the present application has Sunitinib base and glucuronic acid in stoichiometric ratio of 1:1 (mole ratios). Glucuronic acid content in the Form-SG2 of Sunitinib Glucuronate ranges from 31.5-33.5 % w/w as determined by titrimetry (on dried basis). Without deviating from the spirit of the invention, said compositions of about 1:1 stoichiometric ratio are found to retain the characteristic XRPD diffraction pattern along with other solid state parameters.

In another embodiment of the present application, the present invention provides a process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), comprising the steps of:
a) providing a solution of Sunitinib base in ethanol at temperature ranging from 20-35 °C;
b) raising the temperature of reaction mixture to a temperature of 50-55 °C;
c) addition of aq. solution of D(-)glucuronic acid of Formula (A) to the reaction mixture, wherein the addition is performed slowly over time duration of 10-30 mins;
d) stirring the reaction mixture for time duration ranging from 30 mins to 1 hr;
e) cooling the reaction mixture to a temperature of 20-30 °C, wherein rate of cooling shall not exceed 1 °C/ minute;
f) subjecting the reaction mixture obtained from step e) to continuous stirring for the time duration of 4-6 hrs;
g) isolating the crystalline Form-SG2 of Sunitinib Glucuronate (I).
The individual steps of the process according to the present invention for preparing crystalline Form-SG2 of Sunitinib Glucuronate

(I) are detailed separately herein below.
Step a) comprises providing a solution of Sunitinib base in ethanol at temperature ranging from 20-35 °C; A solution of Sunitinib base is provided in ethanol at an ambient temperature of 20-35 °C. Amount of ethanol used to provide the said solution ranges from 10-30 times v/w (mL/g) w.r.t. the weight of Sunitinib base. The reaction mixture is stirred for time duration of 10 mins to 1 hr depending upon dissolution achieved.
Step b) comprises raising the temperature of reaction mixture to a temperature of 50-55 °C, wherein the raising of temperature is carried out in a gradual manner.
Step c) comprises addition of aq. solution of D(-)glucuronic acid to the reaction mixture, wherein the addition is performed slowly over time duration of 10-30 mins;
At the elevated temperature of 50-55 °C as achieved in step b) aq. solution of D (-) glucuronic acid is added to the reaction mixture. The addition of aq. solution of D(-)glucuronic acid to the reaction mixture is performed slowly over time duration of 10-30 mins. Aq. solution of D(-)glucuronic acid used in this step has concentration of 15-25 % w/w and amount of Glucuronic acid used is at least 1.1 moles w.r.t. 1 mole of Sunitinib base. Molar ratio of Glucuronic acid may also be greater than 1.1 mole of Glucuronic acid w.r.t. 1 mole of Sunitinib base to maintain the defined stoichiometric parameters of the end product. In this step initially a clear solution is observed and slight solid material emission starts after about 10-15 mins.
Step d) comprises stirring the reaction mixture for time duration ranging from 30 mins to 1 hr, wherein the reaction mixture obtained from step c) is subjected to continuous stirring for time duration of 30 mins to 1 hr.

Step e) comprises cooling the reaction mixture to a temperature of 20-30 °C, wherein rate of cooling shall not exceed 1 °C/ minute. Controlled rate of cooling is essential for obtaining the end product complying with the purity parameters and the pre-defined characteristic solid state features.

Step f) comprises subjecting the reaction mixture obtained from step e) to continuous stirring for the time duration of 4-6 hrs, wherein the cooled reaction mixture obtained from step e) is stirred continuously for the time duration of 4-6 hrs till the solid material emission from reaction mixture is complete.

Step g) comprises isolating the crystalline Form-SG2 of Sunitinib Glucuronate (I).
The reaction mass obtained from step f) is filtered to get a solid material. Filtration may be performed by any conventional method known to the person having skill in the art. The solid material obtained after filtration is given washing with chilled ethanol. The wet solid material is then dried at a temperature of not less than 50 °C for time duration of 45-75 hrs to obtain the crystalline Form-SG2 of Sunitinib Glucuronate (I). Drying may be performed under reduced pressure conditions for e.g. by using vacuum.

Process of isolating crystalline Form-SG2 of Sunitinib Glucuronate may also comprise other processes but not limited to conventional processes including scrapping, if required filtering from slurry and drying, which may be carried out at room temperature or a bit raised temperature for the suitable durations.

The moisture content of the final API i.e. crystalline Form-SG2 of Sunitinib Glucuronate obtained by the process of the present invention ranges from 2.8-3.8 % w/w (By KF method). TGA results for crystalline Form-SG2 of Sunitinib Glucuronate also corroborates the findings of moisture content determination by KF method. The theoretical percentage of moisture content corresponding to one molecule of water in Sunitinib Glucuronate is ~ 2.95 % w/w. Thus in an embodiment of the present application, crystalline Form-SG2 of Sunitinib Glucuronate is a monohydrate form.

The merit of the process according to the present invention resides in that - product obtained after recovery is obtained directly as crystalline Form-SG2 in high yield. Said material is found to be a very stable crystal lattice which is adequately stable to handle and store for longer time without any significant or measurable change in its morphology. Crystalline Form-SG2 of Sunitinib Glucuronate retains its characteristic features in stability studies even up to 6 months, wherein the physicochemical properties remain substantially the same. This stable form thus, offers various advantages in terms of storage, shelf life, solubility, safety profile, improved physical and/or chemical properties and favorable impurity profile. Substantially pure Form-SG2 of Sunitinib Glucuronate obtained according to the process of the present invention results in the final API purity by HPLC of more than 99.5 % w/w.

The process related impurities, including unreacted intermediates, side products, degradation products, residual solvents and other medium dependent impurities, that appear in the impurity profile of the Sunitinib Glucuronate may be substantially removed by the process of the present invention resulting in the formation of pure crystalline Form-SG2 of Sunitinib Glucuronate. In view of maintaining the equilibrium to the impurity profile compliance, the process may require in-process quality checks to avoid unnecessary repetitions of the same process steps.

Another embodiment of the present invention provides Form-SG2 of Sunitinib Glucuronate, prepared according to the process of this invention, wherein crystalline Form-SG2 is characterized by:

a) X-ray powder diffraction pattern substantially according to Fig-1;
b) Differential Scanning Calorimetry ("DSC") curve substantially according to Fig-2; and
c) Thermo-Gravimetric Analysis (TGA) curve substantially according to Fig-3.

In a still further embodiment of the present application, it provides stable crystalline Form-SG2 of Sunitinib Glucuronate, characterized by XRPD pattern comprising of at least three 20° peaks selected from the XRPD peak set of 3.9, 14.6, 18.4, 25.6 and 27.6 ± 0.2 29°, wherein diffraction angle peak at about 18.4 ± 0.2 29° is a single un-split peak and DSC isotherm comprising of at least one endothermic peak ranging between 115 to 130 °C. Besides endothermic peak ranging between 115 to 130 °C, DSC isotherm of crystalline Form-SG2 of Sunitinib Glucuronate may also show presence of other endothermic peaks.

Crystalline Form-SG2 of Sunitinib Glucuronate is further characterized by X-ray powder diffraction pattern comprising of diffraction angle peaks at about 7.9, 11.8, 20.9, 23.7, 26.7 ± 0.2 29°. In a preferred embodiment of the present invention, the diffraction angle peaks at about 3.9, 11.8 and 18.4 ± 0.2 29° are characterized by relative intensities of at least 20%. Diffraction angle peak at about 18.4 ± 0.2 29° is preferably a single un-split peak.

The characteristic peaks and the corresponding d-spacing values of the crystalline Form-SG2 of Sunitinib Glucuronate obtained by the process of the present invention are tabulated in the Table-1.

Table-1: Characteristic XRPD Peaks of Crystalline Form-SG2 of Sunitinib Glucuronate
Minor variations in the observed 2 0° angles values may be expected based on the analyst person, the specific XRPD diffractometer employed and the sample preparation technique. Further possible variations may also be expected for the relative peak intensities, which may be largely affected by the non-uniformity of the particle size of the sample. Hence, identification of the exact crystalline form of a compound should be based primarily on observed 2 theta angles with lesser importance attributed to relative peak intensities. The 2 theta diffraction angles and corresponding d-spacing values account for positions of various peaks in the X-ray powder diffraction pattern. D-spacing values are calculated with observed 2 theta angles and copper K a wavelength using the Bragg equation well known to those of having skill in the art of XRPD diffractometry science.
In view of possibility of marginal error in the assigning 2 theta angles and d-spacing, the preferred method of comparing X-ray powder diffraction patterns in order to identify a particular crystalline form is to overlay the X-ray powder diffraction pattern of the unknown form over the X-ray powder diffraction pattern of a known form. For example, one skilled in the art can overlay an X-ray powder diffraction pattern of an unidentified crystalline form of Sunitinib Glucuronate over FIG. 1 and readily determine whether the X-ray diffraction pattern of the unidentified form is substantially the same as the X-ray powder diffraction pattern of the crystalline Form-SG2 of this invention. If the X-ray powder diffraction pattern is substantially the same as FIG. 1, the previously unknown crystalline form of Sunitinib Glucuronate can be readily and accurately identified as the crystalline Form-SG2 of this invention.

The crystalline Form-SG2 of Sunitinib Glucuronate described herein may be characterized and analyzed by X-ray powder diffraction pattern (XRPD) on a Bruker AXS D8 Advance Diffractometer using X-ray source - Cu Ka radiation using the wavelength 1.5418 A and lynx Eye detector. DSC was done on a Perkin Elmer Pyris 7.0 instrument. Illustrative examples of analytical data for the Form-SG2 of Sunitinib Glucuronate obtained in the examples are set forth in the Figs. 1-3.

Besides better physical/chemical properties, the crystalline Form-SG2 of Sunitinib Glucuronate of the current application may further provide advantage in terms of solubility of the drug and hence provides possibility of better bioavailability and pharmacological profile.
In a further embodiment according to this patent's specification, the invention also relates to a composition containing crystalline Form-SG2 of Sunitinib Glucuronate.

The crystalline Form-SG2 of Sunitinib Glucuronate obtained by the process of the present application may be formulated as solid compositions for oral administration in the form of capsules, tablets, pills, powders or granules. In these compositions, the active product is mixed with one or more pharmaceutically acceptable excipients. The drug substance can be formulated as liquid compositions for oral administration including solutions, suspensions, syrups, elixirs and emulsions, containing solvents or vehicles such as water, sorbitol, glycerin, propylene glycol or liquid paraffin.

The compositions for parenteral administration can be suspensions, emulsions or aqueous or non-aqueous sterile solutions. As a solvent or vehicle, propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, and injectable organic esters, e.g. ethyl oleate, may be employed. These compositions can contain adjuvants, especially wetting, emulsifying and dispersing agents. The sterilization may be carried out in several ways, e.g. using a bacteriological filter, by incorporating sterilizing agents in the composition, by irradiation or by heating. They may be prepared in the form of sterile compositions, which can be dissolved at the time of use in sterile water or any other sterile injectable medium.

Pharmaceutically acceptable excipients used in the compositions comprising crystalline Form-SG2 of Sunitinib Glucuronate, of the present application include, but are but not limited to diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, pre-gelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, Croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants, waxes and the like. Other pharmaceutically acceptable excipients that are of use include but not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.

Pharmaceutically acceptable excipients used in the compositions of crystalline Form-SG2 of Sunitinib Glucuronate of the present application may also comprise to include the pharmaceutically acceptable carriers used for the preparation of solid dispersion, wherever utilized in the desired dosage form preparation.

EXAMPLE
Example-Ol: PROCESS FOR PREPARATION OF SUNITINIB GLUCURONATE FORM-SG2

20 mL ethanol was charged into a 100 mL round bottomed flask at ~30°C and 1 g Sunitinib base was added to it. The reaction mass was stirred for 15 mins and then its temperature was increased to ~ 55 °C. After this, 0.536 g of D (-)-Glucuronic acid (dissolved in 2.5 mL DM water) was slowly added to the reaction mixture over a time duration of ~ 15 mins, wherein the reaction mass initially turned into a clear solution and then slowly a solid material started emitting. The reaction mass was further stirred for 30 mins followed by cooling to a temperature of ~ 25 °C. Stirring was further continued for 5 hrs. The solid material obtained was then filtered and washed with 2.0 mL chilled ethanol. The wet solid obtained was then suck dried and unloaded. Still further drying of the solid material was performed under vacuum for -48 hrs at -50 °C, to obtain ~ 1.4 g of yellow crystalline powder of Sunitinib Glucuronate Form-SG2, characterized by XRPD pattern according to Fig-1; "DSC" curve according to Fig-2 and TGA pattern according to Fig-3. Yield: 94 % Moisture Content (By KF method): 3.21 % w/w

Example-02: PROCESS FOR PREPARATION OF SUNITINIB GLUCURONATE FORM-SG2

500 mL ethanol was charged into a 1 L 4-neck round bottomed flask at ~25 °C and 25 g Sunitinib base was added to it. The reaction mass was stirred for -10 mins and then its temperature was increased to ~ 50 °C. After this, 13.4 g of D (-)-Glucuronic acid (dissolved in 62.5 mL DM water) was slowly added to the reaction mixture over a time duration of ~ 15 mins, wherein the reaction mass initially turned into a clear solution and then slowly a solid material started emitting. The reaction mass was further stirred for 50 mins followed by cooling to a temperature of ~ 20 °C. Stirring was further continued for 6 hrs. The solid material obtained was then filtered and washed with 75 mL chilled ethanol. The wet solid obtained was then suck dried and unloaded. Still further drying of the solid material was performed under vacuum for -72 hrs at 55 °C, to obtain - 34.2 g of yellow crystalline powder of Sunitinib Glucuronate Form-SG2, characterized by XRPD pattern according to Fig-1; "DSC" curve according to Fig-2 and TGA pattern according to Fig-3. Yield: 91.98% Moisture Content (By KF method): 3.55 % w/w While the foregoing provides a detailed description of the preferred embodiments of the invention, it is to be understood that the descriptions are illustrative only of the principles of the invention and not limiting. Furthermore, as many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.

We Claim:

1. A process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), comprising the steps of:
2.
2.
a) providing a solution of Sunitinib base in ethanol at temperature ranging from 20-35 °C;

b) raising the temperature of reaction mixture to a temperature of 50-55 °C;

c) addition of aq. solution of D(-)glucuronic acid of Formula (A) to the reaction mixture, wherein the addition is performed slowly over time duration of 10-30 mins;

d) stirring the reaction mixture for time duration ranging from 30 mins to 1 hr;

e) cooling the reaction mixture to a temperature of 20-30 °C, wherein rate of cooling shall not exceed 1 °C/ minute;

f) subjecting the reaction mixture obtained from step e) to continuous stirring for the time duration of 4-6 hrs;

g) isolating the crystalline Form-SG2 of Sunitinib Glucuronate (I).

2. A process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), according to claim 1, wherein isolation of crystalline Form-SG2 of Sunitinib Glucuronate (I) in step g) further comprises the steps of-

i. filtering the solid material from the reaction mass;
ii. washing the obtained solid material with chilled ethanol;
iii. drying the solid material obtained in step
ii) at a temperature not less than 50 °C for time duration of 45-75 hrs to obtain the crystalline Form-SG2 of Sunitinib Glucuronate (I).

3. A process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), according to claim 1, wherein aq. solution of D(-)glucuronic acid used in step c) has concentration of 15-25% w/w.

4. A process for preparing crystalline Form-SG2 of Sunitinib Glucuronate (I), according to claim 1, wherein amount of Glucuronic acid used is at least 1.1 moles w.r.t. 1 mole of Sunitinib base.

5. Crystalline Form-SG2 of Sunitinib Glucuronate (I) prepared according to the process of claim-1, wherein the said Form-SG2 is characterized by X-ray powder diffraction pattern comprising of at least three 20° peaks selected from the XRPD peak set of 3.9, 14.6, 18.4, 25.6 and 27.6 ± 0.2 28°, wherein diffraction angle peak at about 18.4 ± 0.2 29° is a single un-split peak.

6. Crystalline Form-SG2 of Sunitinib Glucuronate (I), characterized by X-ray powder diffraction pattern comprising of at least three 20° peaks selected from the XRPD peak set of 3.9, 14.6, 18.4, 25.6 and 27.6 ± 0.2 28°, wherein diffraction angle peak at about 18.4 ± 0.2 20° is a single un-split peak and DSC isotherm comprising of at least one endothermic peak ranging between 115 to 130 °C.

7. Crystalline Form-SG2 of Sunitinib Glucuronate (I) according to claim 6, further characterized by X-ray powder diffraction pattern comprising of diffraction angle peaks at about 7.9, 11.8, 20.9, 23.7, 26.7 ± 0.2 20°.

8. Crystalline Form-SG2 of Sunitinib Glucuronate (I) according to claim 6, further characterized by X-ray powder diffraction pattern substantially according to Fig-1, wherein diffraction angle peak at about 18.4 ± 0.2 20° is a single un-split peak; DSC isotherm substantially according to Fig-2 and TGA curve substantially according to Fig-3.

9. Crystalline Form-SG2 of Sunitinib Glucuronate (I) according to claim 6, characterized by DSC isotherm comprising at least one endothermic peak ranging between 115 to 130 °C and moisture content of 2.8-3.8 % w/w (By KF method).

10. A pharmaceutical composition comprising crystalline Form-SG2 of Sunitinib Glucuronate (I), together with one or more pharmaceutically acceptable excipients.